Drug Trial Radar · NCT02073279
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Last checked: Nov 20, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Aug 5, 2014
Primary completion
Oct 12, 2018
Study completion Jan 31, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Feb 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.
Conditions
- Neuromyelitis Optica (NMO)
- NMO Spectrum Disorder (NMOSD)
Interventions
SatralizumabDrug
Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
PlaceboDrug
Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) PeriodTime frame: Up to Week 216
Locations
58 sites in 15 countries. Site status is shown where the registry gives one.
University of Colorado Denver -; Neurology
Aurora, Colorado
University of Miami UHealth Professional Arts Center
Miami, Florida
The MS Center of Vero Beach
Vero Beach, Florida
Columbus Research and Wellness
Columbus, Georgia
University of Chicago; Neurology
Chicago, Illinois
Consultants in Neurology Ltd
Northbrook, Illinois
OSF Saint Francis Medical Center
Peoria, Illinois
University of Kansas Medical Center
Kansas City, Kansas
MidAmerica Neuroscience Institute
Prairie Village, Kansas
University of Michigan Health System
Ann Arbor, Michigan
Wayne State University - Comp Clinic and MS. Center
Detroit, Michigan
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
The Neurological Institute PA
Charlotte, North Carolina
OhioHealth Research Institute
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
Central Texas Neurology Consultants
Round Rock, Texas
UT Medicine San Antonio
San Antonio, Texas
Virginia Commonwealth University
Richmond, Virginia
Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
Milwaukee, Wisconsin
Medical Help Center EOOD
Dobrich, Bulgaria
MMA-MHAT Pleven - Clinic for Neurology
Pleven, Bulgaria
UMHAT 'Dr. Georgi Stranski', EAD
Pleven, Bulgaria
MHATNP Sveti Naum EAD
Sofia, Bulgaria
UMHAT Alexandrovska, EAD
Sofia, Bulgaria
MS Clinical Trials Group
Vancouver, British Columbia, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Centre hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Klinicki bolnicki centar Osijek
Osijek, Croatia
LTD Helsicore
Tbilisi, Georgia
Pineo Medical Ecosystem LTD
Tbilisi, Georgia
S.Khechinashvili Tbilisi State Medical University Clinic Ne
Tbilisi, Georgia
PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
Catania, Sicily, Italy
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Hospital Universiti Sains Malaysia [Neurology]
Kubang Kerian, Kelantan, Malaysia
Philippine General Hospital
Manila, Philippines
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
Katowice, Poland
Miedzyleski Szpital Specjalistyczny w Warszawie
Warsaw, Poland
San Juan MS Center
Guaynabo, Puerto Rico
SC Clubul Sanatatii SRL
Campulung Muscel, Romania
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.